Anchiano Therapeutics Ltd.·3

Dec 31, 4:09 PM ET

Gabriel Capital Management Ltd. 3

3 · Anchiano Therapeutics Ltd. · Filed Dec 31, 2019

Insider Transaction Report

Form 3
Period: 2019-06-30
Holdings
  • Ordinary Shares, no par value per share

    (indirect: See Footnote)
    5,034,150
  • Warrants (right to buy)

    (indirect: See Footnote)
    Exercise: $1.93Exp: 2023-06-29Ordinary Shares (3,834,396 underlying)
Footnotes (3)
  • [F1]The ordinary shares, no par value (the "Ordinary Shares"), of Anchiano Therapeutics Ltd. (the "Issuer") are held as American Depository Shares ("ADSs"), with each ADS representing five Ordinary Shares.
  • [F2]Gabriel Capital Management Ltd. (the "Reporting Person") is the management company to Shavit Capital Fund III (US), L.P. ("Shavit III") and certain other affiliated funds (collectively with Shavit III, the "Shavit Funds"). Gabriel Leibler ("Mr. Leibler") is the sole shareholder of the sole shareholder of the Reporting Person. As of the filing date of this Form 3: Shavit III held 611,261 ADSs, representing 3,056,305 Ordinary Shares, and warrants exercisable for up to 2,314,286 Ordinary Shares; and the other Shavit Funds held in the aggregate 395,569 ADSs, representing 1,977,845 Ordinary Shares, and warrants exercisable for up to 1,520,110 Ordinary Shares. Pursuant to Rule 16a-1(a)(2) under the Securities Exchange Act of 1934, as amended, each of the Reporting Person's, each Shavit Fund's and Mr. Leibler's beneficial ownership is limited to its pecuniary interest, if any, in such securities.
  • [F3]The warrants are currently exercisable.

Documents

1 file
  • 3
    anchiano_fm3jan12020.xmlPrimary